



PharmaMar Group Reports Q1 2016 Financial Results

- **Total net sales up 16% as business growth enabled record first-quarter sales**
- **Yondelis[®] achieved 22.8 million euro in sales (+15%), the highest quarterly figure since launch**

Madrid, 28 April 2016 – The PharmaMar Group reported 42.1 million euro in total revenues in the first quarter of 2016, of which 40 million euro were group net sales, 16% more than in the same period of 2015.

Both the Biopharmaceutical and Consumer Chemicals divisions increased revenues in the quarter. Biopharmaceutical net sales amounted to 24.7 million euro, a 15% increase year-on-year. Of that figure, 22.8 million euro was net sales of Yondelis[®] in the territories where PharmaMar is leads commercialisation. That was a 15% increase over the same period of 2015 and the highest quarterly sales of Yondelis[®] since the drug was launched.

The Consumer Chemicals area reported 15.8 million euro in revenues in the period, an 18% increase year-on-year.

Other revenues in the first quarter included 1.8 million euro in royalties on Yondelis[®].

The schedule of milestone payments under the 2011 coordination agreement with Janssen L.P. concluded in 2015, and no revenues were recognised under this heading in 2016. Janssen L.P, launched Yondelis[®] late in 2015 in the US following FDA approval and PharmaMar will begin to collect additional royalties on sales in the US.

Research and development expenditure continued to increase in 2016. The advanced status of the product pipeline and the fact that there are Phase III trials are under way or about to commence requires that the sizeable R&D expenditure of previous years be continued in 2016. Total spending on R&D and innovation

amounted to 18.7 million euro in the first quarter, compared with 12.6 million euro (net) in the same period of 2015.

This increase in R&D and innovation expenditure and the conclusion of the milestone payments resulted in group EBITDA being negative in the amount of -3.9 million euro, down from a positive 9.5 million euro in the first quarter of 2015, which included a milestone payment of 10 million dollars (8.8 million euro).

As a result, the Group reported an attributable net loss of -7.1 million euro (vs. +6.5 million euro in 1Q15).

About PharmaMar

PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumour drugs obtained from the sea. PharmaMar has a rich pipeline of pre-clinical candidates and a major R&D programme. The company develops and markets YONDELIS® in Europe and has three other compounds in clinical development for treating solid and haematological tumours: plitidepsin, PM1183 and PM184. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, the United Kingdom, Belgium and the USA. PharmaMar also has a majority stake in other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website: www.pharmamar.com

Important note

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

Further information from:

Communication:

Paula Fernández – Media Relations Manager
pfalarcon@pharmamar.com
Mobile: +34 638796215
Phone: +34 918466000



Investor relations:

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets
investorrelations@pharmamar.com
Phone: +34 914444500
For more information, visit our website: www.pharmamar.com

###